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the innate immune system, driven by type
I IFN, uses modulation of the extracellular
environment to inhibit viruses.
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Interferon-stimulated genes (ISGs) act in concert to
provide a tight barrier against viruses. Recent studies
have shed light on the contribution of individual ISG
effectors to the antiviral state, but most have exam-
ined those acting on early, intracellular stages of
the viral life cycle. Here, we applied an image-based
screen to identify ISGs inhibiting late stages of influ-
enza A virus (IAV) infection. We unraveled a directly
antiviral function for the gene SERPINE1, encoding
plasminogen activator inhibitor 1 (PAI-1). By target-
ing extracellular airway proteases, PAI-1 inhibits
IAV glycoprotein cleavage, thereby reducing infec-
tivity of progeny viruses. This was biologically rele-
vant for IAV restriction in vivo. Further, partial PAI-1
deficiency, attributable to a polymorphism in human
SERPINE1, conferred increased susceptibility to IAV
in vitro. Together, our findings reveal that mani-
pulating the extracellular environment to inhibit the
last step in a virus life cycle is an important mecha-
nism of the antiviral response.
INTRODUCTION
As obligate intracellular parasites, the fate of viruses is intricately
linked to the metabolism of their host cells. Viruses exploit host
cell mechanisms throughout their life cycle, from entry to replica-
tion, assembly and egress, and finally maturation. Each step in
this cycle is a potential point for antiviral intervention.
Virus-infected cells produce interferons (IFNs) that trigger
transcriptional upregulation of IFN-stimulated genes (ISGs)
(reviewed in Schneider et al., 2014). The combined action of hun-
dreds of expressed ISG proteins creates multiple lines of de-fense against viral infection. It is not surprising that different
ISGs block different pathways and have varying potency against
different classes of viruses (Schoggins et al., 2014). Our knowl-
edge of ISG effector functions has been somewhat biased to-
ward inhibition of early replication stages, such as entry, or viral
translation initiation. However, viral assembly and release have
proven to be an Achilles heel for viruses and are the targets of
therapeutic small molecules (influenza A virus [IAV] neuramini-
dase inhibitors; HIV-1 protease inhibitors) and intrinsic ISGs
such as tetherin (Neil et al., 2008) or viperin (Wang et al., 2007).
In this study, we established a screen that would also uncover
host factors inhibiting late stages of the viral replication cycle, us-
ing IAV as a model virus. Applying an approach that accurately
monitors several rounds of viral replication in the presence of sin-
gle overexpressed ISGs, we discovered a direct antiviral function
of the well-known gene SERPINE1, which encodes PAI-1 (Ny
et al., 1986). We demonstrate that PAI-1 inhibits IAV maturation
by targeting host proteases needed for viral glycoprotein cleavage
and that this is physiologically relevant in natural proteolytic land-
scapes both in vitro and in vivo. Finally, we link a human genetic
polymorphism in extracellular PAI-1 production to enhanced IAV
susceptibility in vitro. In all, we show that shaping the extracellular
environment can be a powerful mechanism in the vast arsenal of
the innate immune response against invading pathogens.
RESULTS
AGain-of-Function Screen Reveals SERPINE1 Encoding
PAI-1 as an Inhibitor of IAV Spread
To identify ISG effectors targeting late stages of the IAV life cycle,
we established a high-throughput, image-based screen using an
extended version of a recently published ISG library comprising
401 cDNAs (Schoggins et al., 2011; Table S1). Human lung
adenocarcinoma cells (A549) were transduced with lentiviral
vectors to express individual ISGs (Figure 1A). After 48 hr, cells
were challenged with IAV WSN/33 (H1N1) at an MOI of 0.01.Cell 160, 631–643, February 12, 2015 ª2015 Elsevier Inc. 631
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Figure 1. High-Throughput Microscopy Screens for Inhibitors of IAV Spread
(A) Screening workflow. Shown are hypothetical effects of expressing inhibitory (antiviral) or non-inhibitory ISGs on single or multiple rounds of virus replication.
Red, transduced cells; green, infected cells; blue, DAPI-stained nuclei.
(B) Effect of 401 single ISGs on IAV spread. ISGs inhibiting more than 2-fold SD in two independent screens are shown in red. Spread ratio, the ratio of infected
cells at 24/8 hpi. A positive control for inhibition is a-HA antibody.
(C) Confirmation assays for selected ISGs on A549 cells or primary NHBE cells. Data are represented as mean ± SEM from n = 6 values in two independent
experiments for A549, and n = 3 for NHBE cells.
(D) SERPINE1(PAI-1)-mediated inhibition of A/Vietnam/1203/2004(HALo), A/California/04/2009, and A/sw/Texas/4199-2/1998 in A549 cells. Empty vector,
negative control; IFITM3 and BST2 (tetherin), positive controls. Data are represented as mean ± SEM from n = 4 independent experiments. One-way ANOVA and
Dunn’s multiple comparison test versus ‘‘empty.’’
(E) ISG-expressing A549 cells were infected with IAVWSN/33 at MOI 0.01, and virus titers were measured by plaque assay onMDCK cells. Data are represented
as mean ± SEM from n = 4 independent experiments.
See also Figure S1.
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‘‘Spread ratio’’ was calculated from the number of infected cells
at 24 hr post-infection (hpi) relative to 8 hpi for each ISG (Figures
1A and S1A).
The screen was performed twice, using independently gener-
ated lentivirus libraries (Figure 1B). a-HA antibody, with a spread
ratio of 2, was a positive control, whereas empty vector con-
trols had a spread ratio of 50 to 60 (Figures S1C and 1B). Nine-
teen ISGs reduced the IAV spread ratio to <20, greater than
twoSDs from the empty vector control in both screens (Figure 1B
and Table S2). Among these ISGs were several broadly acting
antiviral factors involved in pattern recognition and IFN signaling,
such as DDX58 (RIG-I), IFIH1 (MDA5), IRF2, IRF7, IL28RA
(IFNLR1), inflammatory cytokines, CCL5 (RANTES), and broadly
acting or IAV-specific inhibitors, such as IFITM3,Mx1, and BST2
(Schneider et al., 2014). IFITM3 and Mx1 act early (IAV entry or
replication), whereas BST2, also known as tetherin, prevents
release of budding virus particles at the host cell surface.
Although conflicting data exist on IAV inhibition by tetherin (Man-
geat et al., 2012; Watanabe et al., 2011; Yondola et al., 2011), it
potently inhibited spread in A549 cells and was subsequently
used as a positive control. We also identified a number of ISGs
with previously uncharacterized antiviral activities: MAP3K14,
ELF1, PMM2, FAM46C, TBX3, SCO2, CRY1, TNFSF10 (TRAIL),
XAF1,MAFF, and SERPINE1 (serine protease inhibitor, member
E1). We validated this set of genes with independently gener-
ated, high-titer lentiviral stocks and A549 cells, as well as normal
human bronchial epithelial cells (NHBE). All but FAM46C, which
did not inhibit virus spread on NHBE cells, were confirmed as
antiviral (Figure 1C). To exclude false positives due to cytotox-
icity, we tested cell proliferation, apoptosis, DNA damage, and
cell death profiles by high-throughput microscopy (HTM) (Fig-
ure S1D). We found that only expression of MAP3K14, the
most potent hit in our screen, and TNFSF10 were cytotoxic rela-
tive to the empty vector control.
Because protease inhibitors have been used clinically to treat
other viruses (e.g., HIV), an endogenous effector with a similar
function was a promising lead. We therefore focused on exploring
the antiviral action of SERPINE1, encoding PAI-1. SERPINE1
expression inhibited spread of various clinical IAV isolates, in-
cluding a derivative of a highly pathogenic avianH5 influenza virus,
modified to remove the polybasic cleavage site in the viral hemag-
glutinin (Steel et al., 2009), A/Vietnam/1203/2004(HALo) (H5N1),
thepandemicA/California/04/2009 (H1N1), andan isolate of swine
origin, A/sw/Texas/4199-2/1998 (H3N2) (Figure 1D). In multi-step
viral growth kinetics, SERPINE1 expression reduced extracellular
IAV WSN/33 titers 10-fold, comparable to inhibition by tetherin
(Figure 1E).
This versatile SERPIN family member has been implicated in
many physiological processes, including regulation of fibrino-
lysis (reviewed in Declerck and Gils, 2013). However, since an
antiviral effector function of PAI-1 protein in the context of the
intrinsic immune response is novel, we set out to determine its
role in restricting IAV infection.
IAV InfectionEnhancesSecretion of PAI-1,which Is Both
Necessary and Sufficient for IAV Inhibition
We first studied the kinetics of SERPINE1 gene expression, as
well as PAI-1 protein production and secretion. We comparedA549 cells and themore relevant in vitromodel of NHBE-derived,
differentiated human ciliated airway epithelium cultures (HAEC),
which mimic both the morphology and physiology of the airway
epithelium in vivo. In A549 cells, SERPINE1 mRNA was slightly
upregulated upon IFN-b stimulation and following infection
with IAV WSN/33 (Figure 2A). This was not due to nonrespon-
siveness of A549 cells, since other ISGs were highly upregulated
(Figures S2A–S2C). TGF-b is known to trigger SERPINE1
expression via the canonical Wnt/b-catenin pathway (He et al.,
2010). Indeed, TGF-b treatment of A549 cells strongly induced
SERPINE1 expression with no or modest effects on ISG15,
IFITM3, and BST2 mRNA levels (Figures S2A–S2D). Stimulation
of SERPINE1 gene expression led to increased intracellular and
extracellular levels of PAI-1 (Figures 2B, 2C, S2E, and S2F).
Consistent with PAI-1 being efficiently secreted, total PAI-1
levels in the supernatant were about 16-fold higher than in
respective IFN-b-treated cell lysates at 24 hr (Figures 2B and
2C). We observed apical secretion of PAI-1 by HAEC after either
IAV WSN/33 infection (Figure 2D) or TGF-b treatment (Fig-
ure S2G). Of note, even mock-treated A549 cells and HAEC
constantly produced and secreted basal levels of PAI-1 that
accumulated over time (Figures 2B–2D). However, PAI-1 is
further upregulated by certain stimuli, including virus infection.
To test possible IAV inhibition by extracellular PAI-1, we added
recombinant active PAI-1 (rPAI-1) to the supernatant of A549
cells during IAV infection. rPAI-1 decreased IAV WSN/33 spread
in a dose-dependent manner (Figure 2E). Conversely, we used a
polyclonal a-PAI-1 antibody that targets the a-helix F of PAI-1 to
neutralize PAI-1’s ability to inhibit proteases (Komissarov et al.,
2005). Strikingly, we found that addition of a-PAI-1 antibody to
A549 cells during infection significantly enhanced IAV spread
compared to the IgG control (Figure 2E).
Thus far, the extracellular environment in our experiments was
defined by components of the growth medium or by proteins
secreted by the cultured cells (endogenous or overexpressed).
To test the potency of PAI-1 in a more natural setting, we exam-
ined IAV growth kinetics on HAEC in the presence or absence of
rPAI-1. Strikingly, addition of rPAI to the apical side of HAEC
significantly reduced IAV growth compared to carrier control,
with 10-fold lower infectivity at 48 hpi (Figure 2F). In contrast,
addition of a-PAI-1 antibody dramatically enhanced IAV growth
as early as 12 hpi and continued throughout the course of infec-
tion. In both A549 cells and HAEC, human parainfluenzavirus 3
(HPIV3) was unaffected by either of these treatments, showing
that the effect was selective for IAV and not due to cytotoxicity
(Figures S2H and S2I).
Experiments probing which stage of the viral life cycle was
affected by PAI-1 showed no effects on early stages, replication,
or egress (Figures S3A–S3E). However, a reduction of progeny
particle infectivity (Figure S3F), together with the extracellular
presenceofPAI-1 (Figure2) and itswell-described functionaspro-
tease inhibitor (Declerck and Gils, 2013), led us to investigate this
activity as themechanistic basis of PAI-1-mediated IAV inhibition.
PAI-1 Targets Airway Proteases Needed
for Extracellular IAV Maturation
Infectivity of IAV progeny particles requires a maturation cleav-
age of the viral hemagglutinin (HA0 to HA1 and HA2), catalyzedCell 160, 631–643, February 12, 2015 ª2015 Elsevier Inc. 633
AD
F
E
B C Figure 2. SERPINE1 Gene Expression Pro-
files and the Role of Extracellular PAI-1 Pro-
tein for IAV Inhibition
(A–C) A549 cells were infected with IAV WSN/33,
treated with IFN-b, or mock-treated. (A) SERPINE1
mRNA expression was normalized relative to
housekeeping gene RPS-11. Fold increase over
pre-treatment control levels is shown. Accumulated
total (B) intracellular and (C) extracellular protein
levels of PAI-1 were determined by ELISA. Data are
represented as mean ± SEM from n = 3 experi-
ments.
(D) HAEC infected with IAV WSN/33 or mock
treated. Accumulated PAI-1 protein in repeated
apical washes was determined by ELISA. Data are
shown as mean ± SEM from n = 3 replicates.
(E) A549 cells were infected with IAV WSN/33 in the
presence of either rPAI-1 (1) or a-PAI-1 antibody (2),
and virus spread was assayed by HTM at 48 hpi.
The number of infected cells was normalized to
buffer (1) or IgG (2). Data are represented asmean ±
SEM from n = 4 independent experiments. Statis-
tical significance relative to empty control was
determined by t tests.
(F) HAECs were infected with IAV WSN/33 in the
presence of either rPAI (1) or a-PAI-1 (2) and buffer
(1) or IgG (2). Progeny virus was collected from
apical washes, and rPAI-1 or a-PAI-1 were re-
plenished after each wash. Virus titers were deter-
mined by plaque assay. Data are shown as mean ±
SEM from n = 3 replicates.
See also Figure S2.by host proteases (Lazarowitz and Choppin, 1975; Skehel and
Waterfield, 1975). We tested whether known HA-cleaving prote-
ases might be direct targets for PAI-1 inhibition. PAI-1 inhibits
protease function by forming a covalent, SDS-stable bond with
the target protease, detectable in gel shift assays. Urokinase
plasminogen activator (uPA), a major target of PAI-1, formed a
complex of 85 kDa with rPAI-1, but not in the presence of the
PAI-1 inhibitor triplaxtinin (Figure 3A). TPCK-trypsin is another
established target of PAI-1 and a prototype chymotrypsin-like
serine protease (Olson et al., 2001). To allow multiple rounds
of IAV infection in cells lacking endogenous HA-cleaving pro-
teases, such as A549, trypsin is typically added in low con-
centrations to the tissue culture medium. We readily detected
PAI-1-trypsin complexes formed in vitro and their degradation
products, which were again absent when triplaxtinin was added
(Figure 3B). Furthermore, we identified human tryptase and hu-
man airway trypsin (HAT) as PAI-1 targets (Figures 3C and 3D).
In contrast, we were unable to detect complexes of PAI-1 and
furin, although this interaction has been previously reported (Fig-
ure S4) (Bernot et al., 2011).
The use of host proteases for maturation is not unique to IAV.
Paramyxoviruses also use airway proteases to cleave their sur-
face fusion (F) glycoprotein, and Sendai virus (SeV) utilizes the
same extracellular airway proteases as IAV (Tashiro et al.,
1992). In contrast, HPIV3 F is cleaved intracellularly by ubiqui-
tous endoproteases such as furin. Using the spread assay and
trypsin as protease, we found that HPIV3 was not inhibited by
PAI-1, whereas IAV WSN/33 and SeV both exhibited reduced634 Cell 160, 631–643, February 12, 2015 ª2015 Elsevier Inc.spread (Figures 3E–3G). SERPINE1* encodes a catalytically
inactive PAI-1 due to a single point mutation in the reactive cen-
ter loop and served as a loss-of-function negative control (Law-
rence et al., 1994). These data clearly demonstrate that PAI-1
targets trypsin-like airway proteases needed for extracellular
virus maturation.
PAI-1 Prevents HA Cleavage of IAV Progeny Particles
Next, we examined the efficiency of HA cleavage in the pres-
ence of PAI-1 and trypsin. We found that rPAI-1 completely
blocked trypsin-mediated cleavage of HA0 into HA1 and HA2
(Figure 4A). Furthermore, expression of wild-type PAI-1, but
not the inactive mutant, reduced the specific infectivity of IAV
Puerto Rico/8/34 grown in the presence of trypsin (Figure 4B).
We found similar results for the extracellular airway proteases
transmembrane protease serine 2 (TMPRSS2) and HAT, both
known HA-cleaving proteases (Hatesuer et al., 2013; Fig-
ure 4C). Treatment with additional trypsin prior to virus titration
restored specific infectivity to the level of virus grown in the
presence of either protease, suggesting that the defect in spe-
cific infectivity was indeed caused by uncleaved HA (Figures
4B and 4C).
We next investigated cleavage efficiency of HA from
different clades: H1 of A/Puerto Rico/8/34, H2 of A/Japan/
305/57, and wild-type H5 of highly pathogenic A/Vietnam/
1203/2004 (Figures 4D and 4E). Both H1PR8 and H2Japan
were uncleaved at baseline but were readily cleaved by either
exogenous trypsin or overexpressed TMPRSS2 (Figure 4D).
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B Figure 3. Protease Targets of PAI-1
(A–D) Representative gel shift assays to show
complexes of recombinant PAI-1 (rPAI-1) and
indicated proteases. 1 mg of rPAI-1 was combined
with increasing amounts of protease, and the
mixture was separated on SDS gels followed by
silver staining. Where indicated, triplaxtinin was
used to inhibit PAI-1 activity.
(E–G) HTM spread assay in the presence of PAI-1
wild-type (SERPINE1), loss-of-function mutant
(SERPINE1*), and controls for HPIV3-GFP (E), IAV
WSN/33 (F), or SeV-GFP (G). Data are shown as
mean ± SEM from at least n = 6 replicates from 2
independent experiments. One-way ANOVA and
Kruskal-Wallis post-test.
See also Figure S4.The slight differences in HA1 size between trypsin- and
TMPRSS2-treated HA has been previously shown to be
caused by altered glycosylation patterns in TMPRSS2-overex-
pressing cells (Bertram et al., 2010a). Further, we found that
wild-type but not mutant PAI-1 inhibited TMPRSS2-mediated
cleavage of both HA subtypes. In contrast, cleavage of
H5Vietnam, which is mediated by endogenous intracellular pro-
teases such as furin, was not impaired by PAI-1 (Figure 4E).
This result is in line with data from PAI-1-furin gel shift assays
(Figure S4) and from experiments with furin-dependent HPIV3
(Figures S2H and S2I), further suggesting that furin is indeed
not inhibited by PAI-1.
Finally, we examined the cleavage state of HA onHAEC. These
cultures produce and secrete intrinsic airway proteases on their
apical side; in fact, they have previously enabled identification of
several proteases that cleave HA (Bo¨ttcher et al., 2006). Addition
of rPAI-1 to HAEC during IAV WSN/33 infection dramatically
reduced HA cleavage, whereas addition of a-PAI-1 increased
cleavage (Figure 4F). These findings are in agreement with our
previous results demonstrating virus growth kinetics in HAEC
(Figure 2F).Cell 160, 631–643,Taken together, these data show that
PAI-1 inhibits IAV spread by reducing
extracellular cleavage maturation of pro-
geny particles and that this mechanism
operates in a physiologically relevant
model of airway epithelium.
Serpine1/Mice Exhibit Enhanced
IAV Infection and More Severe
Disease Pathology
To examine the role of PAI-1 during IAV
infection in vivo, we infected Serpine1/
 orSerpine1+/+ (B6) control mice intrana-
sally with IAVs Puerto Rico/8/34, WSN/
33, or vesicular stomatitis virus (VSV) as
a control. Serpine1 was transcriptionally
upregulated in B6 mouse lungs upon
IAV infection (Figure 5B). We also de-
tected increasing levels of murine PAI-1
(mPAI-1) in mouse lungs over the courseof IAV infection with a 10-fold increase at 5 dpi compared to
PBS-treated B6 (Figure 5C). Both Serpine1 mRNA and mPAI-1
protein were undetectable in Serpine1/ lung homogenates.
IAV-infected Serpine1/ mice exhibited significant weight loss
and succumbed to infection on average 1 day earlier than B6
parental mice (Figures 5D, 5E, 5G, and 5H). This difference was
not observed in mice infected with VSV control (Figure S5A).
Despite the modest difference in survival, lung IAV titers at late
times of infection were significantly elevated in Serpine1/ (Fig-
ures 5F and 5I), which correlated with the levels of mPAI-1. Keller
et al. (2006) used Serpine1/ mice to study the effect of influ-
enza virus infection on thrombosis, and they found no impact
of PAI-1 on IAV infection, as measured by the amount of viral
RNA at day 4 dpi. However, given the role of PAI-1 in blocking
viral maturation, the levels of infectious virus particles (Figures
5F and 5I) are a more relevant measure. Serpine/+ mice ex-
hibited an intermediate phenotype with respect to weight loss,
survival, and murine lung PAI-1 levels, indicating a co-dominant
effect of PAI-1 on IAV infection (Figure S5B).
Serpine1/ lungs were increased in size at 5 days post-IAV
infection, with enhanced necrosis compared to lungs from B6February 12, 2015 ª2015 Elsevier Inc. 635
A B
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D
E F
Figure 4. Effect of PAI-1 on Maturation of IAV HA
(A, D, and E) BHK cells were transfected in serum-free MEM to express HA of different origins. Whole-cell lysates were analyzed by western blot. HA cleavage
products HA1 and HA2 are indicated, and relative band intensities are shown at the bottom of the gel.
(A) HA of A/Puerto Rico/8/34 origin. Shown are cells treated with TPCK-trypsin, TPCK-trypsin and rPAI-1, or buffer.
(B) BHK cells were transfected to express GFP as negative control, PAI-1 wild-type (SER1), or loss-of-function mutant (SER*) and then challengedwith IAV Puerto
Rico/8/1934 in the presence of TPCK-trypsin. Supernatants were harvested and assayed for infectivity by focus forming assay onMDCK cells and for viral RNA by
qRT-PCR. Plaque assays were performed in duplicate with or without additional post-harvest incubation with TPCK-trypsin. Specific infectivity was determined
by calculating the ratio of FFU to vRNA copies, and values were normalized to GFP control. Data are shown as mean ± SEM from n = 6 replicates from 2 in-
dependent experiments.
(legend continued on next page)
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controls (Figure 5A). Bleeding into alveoli was slightly enhanced
in infected Serpine1/ lungs at 4 dpi, which might be expected
given PAI-1’s role in fibrinolysis (Figure S5C). Cytokine expres-
sion was elevated in IAV-infected Serpine1/ lungs compared
to B6 control lungs, indicating increased inflammation (Fig-
ure S5D). In contrast, cytokine levels in uninfected lungs or in
lungs frommice intranasally challenged with poly(I:C) were com-
parable between genotypes (Figure S5E). Thus, the increased
weight loss and death observed in Serpine1/ mice during
IAV infection cannot be simply attributed to a global upregulation
of cytokines. Whereas cytokine levels began to decrease in IAV-
infected B6 lungs at 5 dpi, suggesting a subsiding infection, they
stagnated in Serpine1/ lungs, indicating an ongoing infection
in Serpine1/mice. This correlated with the presence of higher
IAV titers in Serpine1/ mice at this late time point.
To further confirm the in vivo phenotype, we generated mu-
rine tracheal epithelial cultures (MTEC) from the trachea of
Serpine1/ or B6 wild-type mice, similar to HAEC. After chal-
lenge with A/X-31(H3N2), we found significantly increased
vRNA and infectious virus in the Serpine1/ cultures at later
times of infection (Figure 5J). These results strengthen the
physiological relevance of Serpine1 as regulator of IAV spread
and a component of the host barrier that restricts IAV infection
in vivo.
Natural PAI-1 Deficiency in Human Fibroblasts Is
Correlated with Increased Spread of IAV
Several single nucleotide polymorphisms (SNPs), often linked to
bleeding disorders, have been described for SERPINE1 (Fay
et al., 1997; Zhang et al., 2005). SNP rs6092 is located in the
signal peptide sequence of SERPINE1 (c.A43T), resulting in sub-
stitution of alanine by threonine (PAI-1 p.A15T) and partial intra-
cellular retention of PAI-1. In fact, a heterozygous rs6092 carrier
had 30% reduced serum PAI-1 and a tendency to hemorrhage
(Zhang et al., 2005). We characterized IAV susceptibility in three
human fibroblast lines with at least one rs6092 allele. Two of
these are heterozygous for SERPINE1 c.A43T (designated as
T/A 4 and 5, Figure 6), and one is homozygous (A/A 6). We
compared them to three control lines, all encoding wild-type
PAI-1 (T/T 1-3).
We found that IAVWSN/33 spread was significantly enhanced
in the three c.A43T fibroblast lines compared to controls (Figures
6A and 6B). This was not due to enhanced replication, at least for
T/A 5 and A/A 6 because the number of infected cells during one
round of replication was similar to controls (Figure 6C). In multi-
cycle growth experiments, we observed some variation between
control lines, which is common, as donors are genetically hetero-
geneous. However, we found that each c.A43T fibroblast line
produced significantly more infectious virus compared to each
of the three controls (Figure 6D).(C) BHK cells were transfected to co-express GFP as negative control, PAI-1 wil
protease. Cells were then challenged, and virus infectivity was analyzed as desc
(D) HA cleavage assay with H1 of A/Puerto Rico/8/34 or H2 of A/Japan/305/57
function (SER*) PAI-1.
(E) HA cleavage assay with H5 of A/Vietnam/1203/2004 origin and wild-type (SE
(F) HA cleavage assay on HAEC infected with IAV WSN/33 in the presence of eit
apical washes at 24 hpi were analyzed.To determine whether this phenotype was selective for IAV,
we challenged the fibroblasts with HPIV3. Indeed, two of our
three c.A43T fibroblast lines, T/A 5 and A/A 6, did not support
increased spread or replication of HPIV3, as determined by
HTM, or in multicycle growth assays (Figures 6E–6G). However
T/A 4 exhibited both enhanced HPIV3 spread and replication
compared to controls, in which we had previously observed
enhanced IAV replication (Figure 6C), suggesting that this cell
line may have other properties unrelated to SERPINE1 that pro-
mote virus replication and spread.
Extracellular PAI-1 levels of c.A43T fibroblast cultures were
about 50% that of controls, which was consistent with previous
reports (Figure 6H; Zhang et al., 2005). We next attempted to
rescue IAV spread inhibition by adding rPAI-1 to the culture me-
dium of A/A 1, T/A 5, and A/A 6 cells during IAV WSN/33 infec-
tion. rPAI-1 dramatically reduced virus spread in T/A 5 and A/A
6 cells down to the level of T/T 1 control cells in a dose-depen-
dent manner. In contrast, control STAT1/ fibroblasts, which
support enhanced spread, but do not harbor c.A43T nor have
reduced extracellular PAI-1 levels, could not be rescued to the
level of T/T 1 controls (Figure 6I).
These results show that a natural extracellular PAI-1 defi-
ciency correlates with increased IAV spread.
DISCUSSION
We identified the serine protease inhibitor PAI-1 as an ISG that
restricted IAV spread, and we characterized its previously unde-
scribed antiviral function. PAI-1 is a 50 kDa glycoprotein and the
main physiological inhibitor of urokinase/tissue plasminogen
activators (uPA/tPA), bothmajor regulators of the fibrinolytic sys-
tem. uPA/tPA convert the zymogen plasminogen into plasmin,
triggering a proteolytic cascade to dissolve blood clots (re-
viewed in Declerck and Gils, 2013). PAI-1 is present in plasma,
platelets, and the extracellular matrix and is secreted by endo-
thelial, smooth muscle, and immune cells in different tissues,
including the airway. Other than uPA/tPA, PAI-1 inhibits multiple
serine proteases of the chymotrypsin type, with varying effi-
ciencies (Irving et al., 2000).
Here, we find three new PAI-1 protease targets: human
tryptase (tryptase Clara; club cell secretory protein), HAT,
andTMPRSS2, all ofwhich are involved in extracellular IAVglyco-
protein cleavage. This finding suggests a role for PAI-1 as an anti-
viral factor by targeting extracellular maturation of IAV particles.
IAV maturation involves cleavage of its surface glycoprotein
HA into HA1 and HA2. These proteins remain linked via a disul-
fide bond (Skehel and Waterfield, 1975), which forms a hinge,
a prerequisite for viral envelope fusion during entry (Klenk
et al., 1975; Lazarowitz and Choppin, 1975). Because IAV does
not encode its own protease, HA cleavage depends on thed-type (SER), or loss-of-function mutant (SER*), and TMPRSS2 or HAT as bait
ribed in (B).
origin in the presence of protease TMPRSS2 and wild-type (SER) or loss-of-
R) PAI-1, or GFP as a negative control.
her rPAI (1) or a-PAI-1 (2) and buffer (1) or IgG (2). Progeny virus particles from
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Figure 5. Role of Serpine1 in Lethal IAV Infection in Mice
(A–F) Wild-type (B6) or Serpine1/ mice were infected intranasally with 36 LD50 of IAV Puerto Rico/8/34. Statistical significance was determined by individual
t tests (D, F, G, and I) or log rank test (E and H).
(A) Representative images of infected lungs 5 dpi.
(B andC) Homogenates of infectedmouse lungswere assayed for Serpine1mRNA levels by qRT-PCR (B) andmPAI-1 protein levels by ELISA (C). Data are shown
as mean ± SEM from n = 5 mice per group.
(D and E) Weight loss (D) and survival (E) of infected mice. Data are shown as mean ± SEM from n = 25 infected B6 or Serpine1/mice, and n = 3 respective PBS
control animals.
(F) Homogenates of infected lungs were assayed for IAV titers by focus forming assay on MDCK cells. Data are shown as mean ± SEM from n = 17 B6 and 11
Serpine1/ mice per day.
(G–I) Wild-type (B6) or Serpine1/mice were infected intranasally with 36 LD50 of IAVWSN/33 andmonitored for weight loss (G) and survival (H). Data are shown
as mean ± SEM from n = 32 infected B6 or Serpine1/mice, and n = 3 respective PBS control animals. IAV lung titers (I) shown as mean ± SEM from n = 9 B6 or
Serpine1/ mice per day.
(legend continued on next page)
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presence of host proteases at the site of IAV replication. Furin
and PC5/6, members of the subtilisin-like family of serine-prote-
ases, are known to cleave HA intracellularly (Horimoto et al.,
1994; Stieneke-Gro¨ber et al., 1992). We could not find evidence
for inhibition of furin by PAI-1. Human tryptase, HAT, TMPRSS2,
TMPRSS13, mosaic serine protease large-form (MSPL), matrix
metalloproteinase 9 (MMP9), and plasmin are known extracel-
lular HA-cleaving proteases (Lazarowitz et al., 1973; reviewed
in Bertram et al., 2010b). Most are members of the chymo-
trypsin-like serine protease family, the ‘‘target family’’ of PAI-1.
Here, we provide direct proof that PAI-1 efficiently inhibits
trypsin- and TMPRSS2-mediated cleavage of HA, and we hy-
pothesize that PAI-1 might inhibit other members of this prote-
ase family as well.
Accessibility to glycoprotein cleavage is a major determinant
of IAV pathogenicity (Bosch et al., 1981). Whether, and at what
efficiency, an HA subtype can be cleaved by a given protease
is determined by its cleavage site sequence. Highly pathogenic
avian H5 and H7 HAs contain a multi-basic cleavage site, which
makes them accessible to ubiquitiously expressed, intracellular
proteases like furin (Bosch et al., 1981). Hence, viral particles
of these subtypes are immediately mature and infectious upon
budding. Less pathogenic IAV HAs, in contrast, contain a single
arginine residue in their cleavage site, whichmakes them depen-
dent on cleavage by extracellular airway proteases, such as
TMPRSS2. Variation in the amino acid sequence surrounding
this arginine alters cleavage efficiency (Galloway et al., 2013).
Recent studies in TMPRSS2/mice revealed a direct influence
on pathogenicity of IAV strains relying on this protease (Hatesuer
et al., 2013; Sakai et al., 2014; Tarnow et al., 2014). In the
absence of TMPRSS2, IAV of H1N1, H3N2, or H7N9 origin
were unable to spread from the trachea to the lungs, making
the mice highly resistant. This was not the case for highly patho-
genic H5N1 virus (Sakai et al., 2014). Thus, sensitivity to PAI-1-
mediated inhibition (or inhibition by other protease inhibitors)
will depend on the nature of the cleaving protease, as well as
on the cleavage efficiency of a specific HA subtype by that pro-
tease (Figure 5). In this regard, it will be interesting to determine
whether the protease inhibitor PAI-1 has differential impact on
pathogenicity of different IAV subtypes in vivo.
Not surprisingly, HA cleavage has been proposed as a target
for antiviral therapy. Synthetic inhibitors, such as morpholinos
or peptide mimetic protease inhibitors, have been used to target
single proteases (Bo¨ttcher-Friebertsha¨user et al., 2011). Leu-
peptin of actinomyces origin, the synthetic drug camostat, or
aprotinin from bovine lungs all have broader antiprotease activity
(Beppu et al., 1997; Lee et al., 1996; Tashiro et al., 1987; Zhirnov
et al., 2011). So does recombinant mucus protease inhibitor
(MPI), the only previously known airway protease inhibitor of hu-
man origin with anti-IAV activity (Beppu et al., 1997). The efficacy
of applying these molecules to restrict IAV has been demon-
strated both in vitro and in vivo and validates HA cleavage inhibi-
tion as an attractive antiviral strategy. Our data show that PAI-1(J) MTECs cultured from B6 or Serpine1/mice were infected with A/X-31(H3N2)
infectious virus titers were determined by TCID50 assay on MDCK cells. Data a
significance was determined by two-way ANOVA.
See also Figure S5.employs this mechanism and is the first known host protease
inhibitor that functions to protect the host during natural IAV
infection.
PAI-1 is a somewhat unconventional ISG, as it is constitu-
tively expressed, but can be further upregulated by IFN and
other cytokines like IL-6, IL-1, TGF-b, and TNF-a (Medcalf,
2007). This is significant because HA-cleaving proteases are
often upregulated by IAV infection, skewing the protease-prote-
ase inhibitor balance in favor of the virus (Kido et al., 2012).
Thus, PAI-1 may tip the balance back toward the host. Its regu-
lation by TGF-b might be particularly relevant during IAV infec-
tions because IAV neuraminidase can activate latent TGF-b
(Carlson et al., 2010). Other sources of TGF-b in the airway dur-
ing infection include secretion by macrophages and by epithe-
lial cells.
It is interesting that upregulation of SERPINE1 gene expres-
sion during infection is not as dramatic as for other ISGs,
possibly reflecting PAI-1’s critical role in other local and sys-
temic physiological processes, where massive overproduction
could be deleterious for blood clotting, cancer metastasis, or
cell adhesion and migration (reviewed in Declerck and Gils,
2013). PAI-1 is the only SERPIN that spontaneously—and
quickly—adopts a latent form in vivo, which provides a regula-
tory mechanism, both spatially and temporally (Berkenpas
et al., 1995).
The respiratory tract is a major portal for virus entry into the
body but is protected by a multilayered antiviral fence. Mucus
acts as a physical extracellular barrier. Mucins and surfactant
proteins in mucus trap and aggregate virus particles outside of
cells or act as decoy receptors inhibiting early steps in the viral
replication cycle (Hartshorn et al., 2006; Reading et al., 2008).
Mucins are present in airways at constitutive levels but are upre-
gulated during inflammation (Turner and Jones, 2009). We now
add PAI-1 as an additional component of this extracellular bar-
rier. PAI-1 is the first extracellular directly antiviral ISG, and its
promiscuity suggests that it may also play an important role in
host defense against other respiratory viruses that rely on this
step in their life cycles.
Many virus families require a maturation cleavage of viral
surface glycoproteins, generally realized by serine proteases.
Some use virus-encoded proteases, such as picornaviruses or
retroviruses (Brody et al., 1992; Lee et al., 1993). Others, such
as paramyxoviruses, orthomyxoviruses, coronaviruses, filovi-
ruses, or arenaviruses, rely on host proteases (Glowacka
et al., 2011; Lenz et al., 2001; Skehel and Waterfield, 1975;
Steinhauer and Plemper, 2012; Volchkov et al., 1998). All are
potentially sensitive to inhibition of their activating proteases
by host or pharmacological protease inhibitors. Indeed, we
show that a single inhibitor, PAI-1, significantly inhibits spread
of IAV and SeV. Further exploration of the virus—activating
protease—host inhibitor troika may open new avenues for anti-
viral intervention and deepen our understanding of virusmatura-
tion and pathogenicity.at MOI = 106. vRNA was quantified from lysedMTEC by qRT-PCR. In parallel,
re shown as mean ± SEM from n = 3 B6 or Serpine1/ MTECs. Statistical
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Figure 6. Susceptibility of PAI-1-Deficient Human Fibroblasts to IAV
(A–H) SV-40-immortalized human fibroblasts from different donors, wild-type (T/T 1-3), heterozygous (T/A 4 and 5), or homozygous (A/A 6) for SERPINE1 SNP
rs6092 were infected with IAV WSN/33 (A–D, H, and I) or HPIV3-GFP (E–G).
(A) Representative images from single wells infected with IAV WSN/33 at 48 hpi.
(B) IAV spread shown as the ratio between number of infected cells at 12/48 hpi.
(C) Percent of infected fibroblasts after one round of replication. Data in (A) and (B) are represented as mean ± SEM from n = 4 independent experiments, each in
triplicate.
(D) IAVWSN/33 growth on fibroblasts. PFU in the supernatants were determined by plaque assay onMDCK cells. Data are represented asmean ±SEM from n = 4
independent experiments. Statistical significance was determined by individual t test, comparing the pooled SNP-carrying cells with the pooled control cells TT2
and TT3 for every time point.
(E) HPIV3-GFP spread shown as the ratio between number of infected cells at 48 and 24 hpi.
(F) Percent of infected fibroblasts after one round of replication. Data in (E) and (F) are represented as mean ± SEM from n = 2 independent experiments, each in
triplicate.
(G) HPIV3-GFP growth on fibroblasts. TCID50 in supernatants were determined on LLC-MK2 cells.
(H) Extracellular PAI-1 levels from IAVWSN/33-infected fibroblasts during spread assay at 48 hpi. Data are shown asmean ± SEM from total n = 8 replicates from
n = 4 experiments.
(I) Rescue of virus inhibition on selected human fibroblast lines by adding rPAI-1 to the cultures during IAV WSN/33 infection. Maximum addition of rPAI-1 (black
bars) was 500 ng, minimum addition (light gray bars) 125 ng. Data are represented as mean ± SEM from n = 4 independent experiments, each in quadruplicate.
One-way ANOVA and Dunnett’s multiple comparison post-test against T/T 1- values of the same condition.
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In conclusion, we identify SERPINE1/PAI-1 as a host factor in-
hibiting IAV spread and show that PAI-1 mechanistically acts by
blocking maturation of progeny IAV particles, thus reducing par-
ticle infectivity. Naturally occurring human genetic variations in
PAI-1 impact the ability of IAV to spread from cell to cell, thus
identifying PAI-1 as a candidate human gene that may influence
susceptibility to IAV and the outcome of infection. In this regard,
it will be of immediate interest to determine whether PAI-1
deficiency might be linked with the severity of human IAV infec-
tion. Finally, our work suggests that localized administration of
PAI-1 to the respiratory tractmight provide a new therapeutic ap-
proach for treating IAV and other respiratory viruses that require
extracellular protease-driven maturation.
EXPERIMENTAL PROCEDURES
High-Throughput Microscopy Screening of Host Factor Library
Using Gateway technology, we transferred a previously published library of
ISGs (Schoggins et al., 2011) from ORFEXPRESS entry clones into a new len-
tiviral expression vector (pSCRPSY), co-expressing TagRFP as a transduction
control and puromycin resistance. A549 cells in 96-well plates were first trans-
duced and then challenged with IAV WSN/33 at MOI 0.01. Due to varying
transduction efficiency between the lentiviral stocks, the percentage of non-
transduced cells was variable. IAV production from non-transduced cells
masked potential inhibitory effects of ISGs and was eliminated by adding pu-
romycin 1 hr prior to IAV infection. Lentiviral transduction was performed in
duplicate plates for each ISG, where one sample was fixed after one round
of replication (8 hpi), defining the number of initial producer cells, and the other
after several rounds of replication (24 hpi). ‘‘Spread ratio’’ was calculated by
dividing the IAV-infected cells at 24 hpi by 8 hpi for each individual ISG over
empty vector-transduced cells (Figures 1A, S1A, and S1B) and yielded results
that were stable over a wide range of transduction efficiencies (Figure S1B). In-
fected cells were detected by staining for IAV nucleoprotein (NP) and HTM
(Figures 1A, S1A, and S1B).
Mice
Mice were housed in an AAALAC-accredited facility in accordance with the
Guide for the Care and Use of Laboratory Animals. All procedures outlined
in the study were approved by The Rockefeller University’s Institutional Animal
Care and Use Committee. Wild-type (C57BL/6J) and Serpine/ (B6.129S2-
Serpine1tm1Mlg/J) breeder pairs were purchased from Jackson Laboratory,
and colonies were established in-house. Six- to ten-week-old mice of both
sexes were used in IAV challenge, and 10- to 14-week-old mice were used
for VSV experiments.
Human Cell Lines
Informed consent was obtained from human subjects according to local reg-
ulations. Samples were subsequently transferred for experimental testing
under respective ethics approvals at INSERM in France and at Rockefeller Uni-
versity in the USA. All protocols involving the use of human tissue were re-
viewed and exempted by The Rockefeller University Institutional Review
Board.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and three tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2015.01.040.
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